Dec 7th, 2017 - New Data on Androgen Receptor Blockade in Breast Cancer: A Review From SABCS 2017 Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Dec 10th, 2017 - Radiation and Immunotherapy: Novel Concepts From SABCS 2017 Interview with Lee S. Schwartzberg MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Jan 16th, 2018 - Evaluation of biomarkers after 5 years of standard therapy for hormone-positive breast cancer may help determine those at risk for recurrence and those who may need further endocrine therapy.
Dec 13th, 2017 - Vered Stearns, MD, of Johns Hopkins School of Medicine in Baltimore, Maryland, reviews controversies in the treatment of early-stage hormone receptor (HR)-positive breast cancer.
Dec 6th, 2017 - Prof Tripathy speaks at a SABCS 2017 press session about data from the MONALEESA-7 phase III clinical trial.
Dec 8th, 2017 - Prof Debu Tripathy speaks with ecancer at SABCS 2017 about the results of the MONALEESA 7 trial of ribociclib for pre/perimenopausal women with HR advanced breast cancer.
Dec 6th, 2017 - Lynn J. Howie, MD, of the U. S. Food & Drug Administration, discusses a pooled analysis of outcomes of older women with hormone receptor–positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine-based therapy (Abstract GS5-06).
Dec 8th, 2017 - Dr Jean Abraham met with ecancer at SABCS 2017 to discuss the PARTNER trial establishing the safety of olaparib added to neoadjuvant platinum chemotherapy for women with triple negative and/or mBRCA breast cancer.
Dec 7th, 2017 - Elizabeth A. Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the growing role of immunotherapy in treating breast disease, the evidence of biomarkers that may be associated with response to therapy, and the opportunities to perform robust correlative studies.
Dec 10th, 2017 - Clinical Updates on Advanced Triple Negative Breast Cancer From SABCS 2017 Interview with Kimberly L Blackwell MD Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Dec 11th, 2017 - Disparities in the Incidence and Mortality of Breast Cancer Based on Patient Subtypes: SABCS 2017 Interview with Kimberly L Blackwell MD Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Dec 7th, 2017 - Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses study findings on a comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive breast cancer (Abstract GS4-03).
Dec 6th, 2017 - Joseph A. Sparano, MD, of Montefiore Medical Center/Albert Einstein College of Medicine, discusses findings that suggest circulating tumor cells 5 years after diagnosis are prognostic for late recurrence in operable stage II–III breast cancer (Abstract GS6-03).
Dec 7th, 2017 - Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase II study findings evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer (Abstract GS4-07).
Dec 7th, 2017 - Harpreet Singh speaks with ecancer at SABCS 2017 about how older women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer who were treated with cyclin-dependent kinase inhibitors 4 and 6 (CDK4/6) achieved progression-free survival at a rate similar to that of younger women.
Dec 6th, 2017 - Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor-positive breast cancer.
Dec 10th, 2017 - SABCS 2017: An Update on Hepatic Pseudocirrhosis in Breast Cancer Interview with Jame Abraham MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Dec 10th, 2017 - SABCS 2017: Key Takeaways From Dr. Jame Abraham Interview with Jame Abraham MD, FACP Interview by Farzanna S Haffizulla MD, FACP, FAMWA
Dec 6th, 2017 - Eun-Sil Shelley Hwang, MD, of Duke University Medical Center, discusses study findings on primary endocrine therapy for estrogen receptor–positive ductal carcinoma in situ (Abstract GS5-05).
Dec 7th, 2017 - Melinda Telli, MD, of the Stanford University School of Medicine, discusses the current status of treatment for advanced TNBC, and new therapeutic strategies now being used for better outcomes.